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Inflammation is a key component of the tumor microenvironment. Two reports published in this issue of
Cancer Cell, Andreu et al. and Erez et al., shed new light on pathways and players involved in the orchestra-
tion of cancer-related inflammation.Figure 1. A Schematic Representation of Diverse Pathways that Orchestrate the Protumor
Function of Myelomonocytic Cells
In different models of carcinogenesis, macrophage polarization is orchestrated by different cells and
molecules (Th2-derived IL-4 or B cell-derived antibodies and immune complexes). TAM can therefore
differ (light blue or green) but they share M2-like cancer-promoting properties.Recruitment of myelomonocytic cells is a
hallmark of cancer-related inflammation
(Mantovani et al., 2008; Pollard, 2004).
Tumor-associated macrophages (TAMs)
have served as a paradigm for the cancer-
promoting actions of hematopoietic cells
(Allavena et al., 2008). TAMs in established
progressing tumors generally fail to ex-
press antitumor activity and have proper-
ties of alternatively activated or M2-like
cells, oriented to the promotion of tissue
remodeling, angiogenesis, and taming of
protective adaptive immunity. Other cells
in the myelomonocytic lineage includ-
ing Tie2+ monocytes, the operationally
defined myeloid-derived suppressor cells
(MDSCs), and mature neutrophils share
properties and protumor functions with
TAMs (Fridlender et al., 2009; Mantovani
et al., 2008; Ostrand-Rosenberg, 2008).
What signals orchestrate the protumor
functions of TAM? Tumor cells produce
molecules that orchestrate mononuclear
phagocyte functions such as colony stimu-
lating factor-1 (CSF-1) or interleukin-10
(IL-10) (Hagemann et al., 2006; Mantovani
et al., 2008; Pollard, 2004) (Figure 1).
A report in this issue of Cancer Cell (Erez
et al., 2010) now shows that in a mouse
model of multistage squamous epithelium
carcinogenesis driven by HPV, tumor cells
also reprogram fibroblasts to promote
inflammation. Cancer-associated fibro-
blasts (CAFs)acquireproinflammatorypro-
perties and promote tumor growth, angio-
genesis, and macrophage recruitment.
Conditioning of CAF is orchestrated by
tumor cells as well as by immune cells as
discussed below. Interestingly, an in-
flammatory signature is present also in
fibroblasts from selected human tumors
(breast and pancreas) characterized by a
desmoplastic response.Hence, fibroblasts
have now emerged as new players incancer-related inflammation (CRI) capable
of considerable plasticity and of shaping
the function of TAMs (Erez et al., 2010).
In the same model of multistage carci-
nogenesis, lymphocytes were found to
orchestrate cancer-related inflammation
by remote control. Antibodies produced
by B cells with the help of CD4+ T cells
localize in the matrix and drive the con-
struction and function of an inflammatory
microenvironment. Dissection of this
pathway has now shed new light on its
cellular and molecular components
(Andreu et al., 2010).
The effector function of antibodies is
mediated by Fcg receptors (FcgRs) or byCancer Cell 17,complement. As true for other compo-
nents of immunity, complement can also
act as a double-edged sword in cancer.
Complement components have indeed
been implicated in the recruitment of
cancer-promoting myelomonocytic cells
(Markiewski et al., 2008). Unequivocal
evidence is now presented that in this
model of epithelial carcinogenesis, anti-
body-mediated cancer promotion is FcgR
dependent (Andreu et al., 2010). The path-
way that emerges can be summarized
as follows (Figure 1): B cells produce
antibodies directed against components
of the extracellular matrix. FcgR engage-
ment leads to mast cell-dependentFebruary 17, 2010 ª2010 Elsevier Inc. 111
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Previewspromotion of angiogenesis and myelomo-
nocytic cell recruitment. Macrophages
directly enhance tumorigenicity in an
FcgR-dependent fashion. Interestingly,
here the culprit of tumor promotion was
on mature TAMs rather than on immature
elements in the myelomonocytic pathway
such as MDSC. Tumor-promoting TAMs
have a M2-like transcriptional profile. B
cell-instructed innate cells are a source of
IL-1, which activates the proinflammatory
properties of CAF (Erez et al., 2010).
The TAM profile reported by Andreu
et al. and previous profiles (Mantovani
et al., 2008) include T cell-attracting anti-
angiogenic chemokines (CXCL10 and
CXCL11). This finding emphasizes the
yin-yang dual potential of the macro-
phage-tumor cell interplay (Allavena
et al., 2008; Mantovani et al., 2008; Os-
trand-Rosenberg, 2008).
These observations raise important
general issues. B cells are a valuable
target in the therapy of autoimmune disor-
ders. Therefore, the definition of a B cell/
antibody/FcgR/macrophage pathway in
cancer-promoting inflammation identifies
potential targets for therapeutic interven-
tion. Similarly, IL-1-blocking strategies
are available or being developed for112 Cancer Cell 17, February 17, 2010 ª2010inflammatory disorders, and in both here
and elsewhere (Dinarello, 2009), IL-1 is
emerging as a key player in CRI.
Myelomonocytic cells are part of a
common pathway of inflammation-medi-
ated cancer promotion (Allavena et al.,
2008; Mantovani et al., 2008; Pollard,
2004). However, the subsets involved
(from classic mature macrophages or
neutrophils to immature myelomonocytic
cells) differ considerably in different
settings (e.g., Andreuet al., 2010;DeNardo
et al., 2009; andFridlenderet al., 2009). In a
mousemodel of metastatic breast cancer,
DeNardo and colleagues (DeNardo et al.,
2009) reported thatmacrophageM2polar-
ization and tumor promotion is driven by
T cell-produced IL-4. Thus, not only can
the subsets be different but so can the
orchestrating signals in different tumors
(Figure 1). Therefore, careful dissection of
the players, conductors and themes in
different human cancers will be required
for the clinical exploitation of our under-
standing of CRI at the bedside.REFERENCES
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Identifying transcriptional program(s) deregulated by oncoproteins is key to understanding the molecular
basis of the disease. In this issue of Cancer Cell, two studies by Martens et al. and Wang et al. provide global
blueprints for transcriptional targets and epigenetic modifications mediated by PML-RARa in acute promye-
locytic leukemia.Acute promyelocytic leukemia (APL) is
characterized by the expression of RARa
fusions and unique sensitivity to all-transretinoic acid (ATRA) treatment. As a result,
it has been the paradigm for studying dif-
ferentiation therapies and more recentlyfor epigenetic therapies. In the past de-
cades, a tremendous amount of effort
has been made to identify the aberrant
